Verastem (VSTM) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

VSTM Verastem

Watchlist

3.7900
-0.1700-4.29%

Close Nov 20 16:00 ET

3.7900
0.00000.00%

Pre 08:00 ET

168.68MMarket Cap-1207P/E (TTM)

Pre-Market

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Byondis Appoints Louis Denis, M.D., as Chief Medical Officer
BusinesswireNov 19 01:11 ET
RBC Capital Maintains Verastem(VSTM.US) With Buy Rating, Maintains Target Price $13
Moomoo NewsNov 7 07:31 ET · Ratings
A. G. P. Maintains Verastem(VSTM.US) With Buy Rating, Cuts Target Price to $14
Moomoo NewsNov 7 07:31 ET · Ratings
Verastem Price Target Lowered to $14 From $20 at Alliance Global Partners
TipRanksNov 7 07:06 ET
Express News | Corrected-Verastem Inc: Qtrly Adj Shr Loss $0.88 (Not '$0.71')
ReutersNov 6 17:09 ET
Verastem Cuts FY24 EPS View to $4.17-$4.23 From $4.25-$4.35, Consensus $4.28
TipRanksNov 6 17:08 ET

Comments

Tonyco

Oct 31 22:49

$Verastem (VSTM.US)$
Pretty damn good run so far. I only managed to hop on in Sept.

Jaguar8

Oct 31 15:01

NEWS

$Verastem (VSTM.US)$
Verastem Oncology Completes Rolling NDA Submission to the FDA for Avutometinib Plus Defactinib as a Treatment for Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer
Verastem Oncology (VSTM) has completed its rolling New Drug Application (NDA) to the FDA for avutometinib plus defactinibcombination therapy for adults with recurrent KRAS mutant low-grade serous ovarian cancer (LGSOC). The company is seeking accelerated approval and priority review, with a potential FDA ap...